Unfractionated Heparin Market to Reach US$1664.4 mn by 2025

Global Unfractionated Heparin Market: Snapshot

Unfractionated heparin is a naturally occurring anticoagulant that is primarily in dialysis and heart lung machines to prevent blood clots as well as for the treatment of blood clotting disorders such as deep venous thrombosis (DVT) and pulmonary embolism. Unfractionated heparin is also highly popular owing to its immediate onset of action, simple laboratory monitoring, short half-life, ability to get reversed (protamine), and low cost.

In the past few years, the vast rise in usage of unfractionated heparin for the treatment of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) along with the massive rise in the number of surgical procedures that take unfractionated heparin as the preferred anticoagulant have spelled growth for the global unfractionated heparin market. Although unfractionated heparin is one of the most primitive forms of heparin, the narrow therapeutic window and risks associated with bleeding act as the major restraints to its uptake, thus stifling the growth prospects of the market to a certain extent. Patent expiration of majority of unfractionated heparin products has created a huge opportunity for generic and biosimilar manufacturers.The global unfractionated heparin market was valued at US$ 955.9 mn in 2016 and is expected to rise to an estimated value of US$1664.4 mn in 2025, expanding at a CAGR of 6.4 % from 2017 to 2025.

Request A Sample-

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=32198

Bovine-based Unfractionated Heparin to Gain Traction as Drug Bodies Propose Re-introduction in Banned Regions

Global unfractionated heparin market has been studied on the basis of two key sources, namely bovine and porcine. The porcine-based unfractionated heparin segment accounted for the dominant share in the overall market in 2016. Bovine-based unfractionated heparin was banned in the U.S. and Europe region post 1990s due to the spread of bovine spongiform encephalopathy (BSE) disease in cattle. However, the Center for Drug Evaluation and Research (CDER), U.S., has recently proposed the re-introduction of bovine-based heparin due to shortage of porcine sourced unfractionated heparin.

Leave a Reply